I would also add that the alzehimers theory has very much changed over the last few years in that the drugs need to be given much earlier. That's what Pfizer is doing in this current trial, so it's not like they are using it for a completely different disease, they are still in the Alzehimers setting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.